Research in IMO
iPS cells as a study tool and model to implement the CRISPR-CAS system in the treatment of Retinal Dystrophies
The ultimate goal of this research is to lay the foundation for the application of cell therapy in the treatment of retinal dystrophies, by implanting healthy cells, obtained from iPS cells, in the patients' affected tissues.
Efficacy and safety of autologous cultivated limbal stem cells transplantation (ACLSCT) for restoration of corneal epithelium in patients with limbal stem cell deficiency.
Long-term safety and follow-up study after autologus cultivated limbal stem cells transplantation for restoretion of corneal epithelium in patients with limbal stem deficiency due to ocular burns.
Mass sequencing of exomes for the identification of new genes and variants responsible for retinal dystrophies
Retinitis pigmentosa, with a prevalence of 1 in 4,000 people and more than one million sufferers worldwide, is the most common retinal dystrophy. These diseases are neurodegenerative and caused by the death of the photoreceptors and cells of the retinal pigment epithelium.
A randomized, double-blind, phase IV clinical study with simulated control for the analysis of the efficacy, safety and tolerability of aflibercept intrevitrea monotherapy compared to aflibercept and concomitant photodynamic therapy in patients with polypodal choroidal vasculopathy.